Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.

Publication Type:

Journal Article

Authors:

Centers for Disease Control and Prevention

Source:

MMWR Morb Mortal Wkly Rep, Volume 61, Issue 40, p.816-819 (2012)

Cited On:

HCV Testing and Linkage to Care

Export Citation:

RIS Format

Top